Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 423 participants.
Also called NCT04610892
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 423 participants
- Sponsor
- Registry
-
NCT04610892 -
2020-000840-75
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Czechia, Hungary, Italy, Japan, Netherlands, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04610892. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2023-11-08 (actual). Results posted on 2025-02-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
- Acronym
- GOLDILOX
- Condition
- Coronary Heart Disease (CHD)
- Intervention (Biological)
- MEDI6570
- Intervention (Biological)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct04610892- Content hash
fbddec3c04df1446f52704fde48d70a2b79e408a12ac239beefc10f4deb78967